Thalys Medical Technology Group Inc. (603716.SS)
CNY 9.69
(-3.77%)
CNY 9.69
(-3.77%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 341.6 Million CNY | -18.81% |
| 2022 | 420.74 Million CNY | -9.25% |
| 2021 | 463.61 Million CNY | 15.33% |
| 2020 | 402 Million CNY | 15.2% |
| 2019 | 348.97 Million CNY | 27.2% |
| 2018 | 274.34 Million CNY | 36.13% |
| 2017 | 201.53 Million CNY | 165.0% |
| 2016 | 76.05 Million CNY | 15.26% |
| 2015 | 65.98 Million CNY | 18.14% |
| 2014 | 55.85 Million CNY | -8.22% |
| 2013 | 60.85 Million CNY | -33.62% |
| 2012 | 91.67 Million CNY | 117.98% |
| 2011 | 42.05 Million CNY | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 324.26 Million CNY | -13.85% |
| 2024 Q3 | 318.96 Million CNY | -1.64% |
| 2024 Q1 | 376.4 Million CNY | 10.19% |
| 2023 Q1 | 474.79 Million CNY | 12.85% |
| 2023 FY | 341.6 Million CNY | -18.81% |
| 2023 Q4 | 341.6 Million CNY | -19.45% |
| 2023 Q3 | 424.07 Million CNY | 2.57% |
| 2023 Q2 | 413.43 Million CNY | -12.92% |
| 2022 Q4 | 420.74 Million CNY | -26.87% |
| 2022 Q3 | 575.3 Million CNY | 12.34% |
| 2022 Q1 | 488 Million CNY | 5.26% |
| 2022 Q2 | 512.13 Million CNY | 4.94% |
| 2022 FY | 420.74 Million CNY | -9.25% |
| 2021 Q2 | 486.21 Million CNY | 4.74% |
| 2021 Q3 | 547.4 Million CNY | 12.59% |
| 2021 Q4 | 463.61 Million CNY | -15.31% |
| 2021 Q1 | 464.18 Million CNY | 15.47% |
| 2021 FY | 463.61 Million CNY | 15.33% |
| 2020 Q1 | 403.57 Million CNY | 15.64% |
| 2020 FY | 402 Million CNY | 15.2% |
| 2020 Q3 | 394.65 Million CNY | 0.47% |
| 2020 Q2 | 392.8 Million CNY | -2.67% |
| 2020 Q4 | 402 Million CNY | 1.86% |
| 2019 FY | 348.97 Million CNY | 27.2% |
| 2019 Q4 | 348.97 Million CNY | -11.81% |
| 2019 Q3 | 395.7 Million CNY | 15.44% |
| 2019 Q2 | 342.78 Million CNY | 4.61% |
| 2019 Q1 | 327.66 Million CNY | 19.44% |
| 2018 Q2 | 304.66 Million CNY | 25.16% |
| 2018 Q1 | 243.4 Million CNY | 20.78% |
| 2018 Q3 | 301.05 Million CNY | -1.18% |
| 2018 FY | 274.34 Million CNY | 36.13% |
| 2018 Q4 | 274.34 Million CNY | -8.87% |
| 2017 Q3 | 164.37 Million CNY | 28.8% |
| 2017 FY | 201.53 Million CNY | 165.0% |
| 2017 Q4 | 201.53 Million CNY | 22.61% |
| 2017 Q2 | 127.62 Million CNY | 22.65% |
| 2017 Q1 | 104.05 Million CNY | 36.82% |
| 2016 Q1 | - CNY | -100.0% |
| 2016 FY | 76.05 Million CNY | 15.26% |
| 2016 Q4 | 76.05 Million CNY | 3.36% |
| 2016 Q2 | 85.81 Million CNY | 0.0% |
| 2016 Q3 | 73.57 Million CNY | -14.25% |
| 2015 Q4 | 65.98 Million CNY | 0.0% |
| 2015 FY | 65.98 Million CNY | 18.14% |
| 2014 FY | 55.85 Million CNY | -8.22% |
| 2013 FY | 60.85 Million CNY | -33.62% |
| 2012 FY | 91.67 Million CNY | 117.98% |
| 2011 FY | 42.05 Million CNY | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Shanghai Runda Medical Technology Co., Ltd. | 1.37 Billion CNY | 75.192% |
| Joinn Laboratories(China)Co.,Ltd. | 1.86 Billion CNY | 81.665% |
| WuXi AppTec Co., Ltd. | 4.73 Billion CNY | 92.787% |
| Autobio Diagnostics Co., Ltd. | 778.28 Million CNY | 56.109% |
| Guangzhou Kingmed Diagnostics Group Co., Ltd. | 248.2 Million CNY | -37.627% |
| Chemclin Diagnostics Co., Ltd. | 110.6 Million CNY | -208.847% |